EUVIMEDEUVIMED entdecken
Open Access

Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection

Tanayott Thaweethai, Sarah E Jolley, Elizabeth W Karlson, Emily B Levitan, Bruce Levy, Grace A McComsey, Lisa McCorkell, Girish N Nadkarni, Sairam Parthasarathy, Upinder Singh, Tiffany A Walker, Caitlin A Selvaggi und 48 weitere

JAMA · 13.06.2023 · 329 (22) · 1934

DOI: 10.1001/jama.2023.8823 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 13.06.2023. Verfasst von Tanayott Thaweethai und 59 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 859-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NICHD NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID . Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and infected individuals.

Objective

To develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections. Design, Setting, and Participants Prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Selection included population-based, volunteer, and convenience sampling. Exposure SARS-CoV-2 infection. Main Outcomes and Measures PASC and 44 participant-reported symptoms (with severity thresholds).

Results

A total of 9764 participants (89% SARS-CoV-2 infected; 71% female; 16% Hispanic/Latino; 15% non-Hispanic Black; median age, 47 years [IQR, 35-60]) met selection criteria. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% [95% CI, 8.8%-11%]) were PASC positive at 6 months. Conclusions and Relevance A definition of PASC was developed based on symptoms in a prospective cohort study. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19FemaleAdultHumansMiddle AgedMaleProspective StudiesPost-Acute COVID-19 SyndromeCohort StudiesDisease ProgressionFatigue

Autor:innen und Institutionen

  • Massachusetts General Hospital, Boston.
  • Harvard Medical School, Boston, Massachusetts.
  • University of Colorado Anschutz Medical Campus, Aurora.
  • Brigham and Women's Hospital, Boston, Massachusetts.
  • University of Alabama at Birmingham.
  • Case Western Reserve University, Cleveland, Ohio.

Förderung

  • NHLBI NIH HHS
  • NICHD NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NIA NIH HHS
  • NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Thaweethai, T., Jolley, S. E., Karlson, E. W., Levitan, E. B., Levy, B., McComsey, G. A., McCorkell, L., Nadkarni, G. N., Parthasarathy, S., Singh, U., Walker, T. A., Selvaggi, C. A., Shinnick, D. J., Schulte, C. C. M., Atchley-Challenner, R., Alba, G. A., Alicic, R., Altman, N., Anglin, K., …, & Goldman, J. D. (2023). Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA, 329(22), 1934. https://doi.org/10.1001/jama.2023.8823

Vancouver

Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934. doi:10.1001/jama.2023.8823

BibTeX
@article{Thaweethai2023,
  author = {Thaweethai, Tanayott and Jolley, Sarah E and Karlson, Elizabeth W and Levitan, Emily B and Levy, Bruce and McComsey, Grace A and McCorkell, Lisa and Nadkarni, Girish N and Parthasarathy, Sairam and Singh, Upinder and Walker, Tiffany A and Selvaggi, Caitlin A and Shinnick, Daniel J and Schulte, Carolin C M and Atchley-Challenner, Rachel and Alba, George A and Alicic, Radica and Altman, Natasha and Anglin, Khamal and Argueta, Urania and Ashktorab, Hassan and Baslet, Gaston and Bassett, Ingrid V and Bateman, Lucinda and Bedi, Brahmchetna and Bhattacharyya, Shamik and Bind, Marie-Abele and Blomkalns, Andra L and Bonilla, Hector and Brim, Hassan and Bush, Patricia A and Castro, Mario and Chan, James and Charney, Alexander W and Chen, Peter and Chibnik, Lori B and Chu, Helen Y and Clifton, Rebecca G and Costantine, Maged M and Cribbs, Sushma K and Davila Nieves, Sylvia I and Deeks, Steven G and Duven, Alexandria and Emery, Ivette F and Erdmann, Nathan and Erlandson, Kristine M and Ernst, Kacey C and Farah-Abraham, Rachael and Farner, Cheryl E and Feuerriegel, Elen M and Fleurimont, Judes and Fonseca, Vivian and Franko, Nicholas and Gainer, Vivian and Gander, Jennifer C and Gardner, Edward M and Geng, Linda N and Gibson, Kelly S and Go, Minjoung and Goldman, Jason D},
  title = {Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {22},
  pages = {1934},
  doi = {10.1001/jama.2023.8823}
}
Kostenlos starten →